Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Pazopanib vs lapatinib

Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 3.08 [0.13, 74.42]
1 study · 150 participants
Very low

Pazopanib plus lapatinib vs lapatinib

Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 3 [0.12, 72.5]
1 study · 152 participants
Very low